<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1998
Commission file number: 000-19788
MENLEY & JAMES, INC.
(Exact name of Registrant as specified in its charter)
Delaware 23-2621602
(State of incorporation) (I.R.S. Employer Identification No.)
125 Strafford Avenue, Suite 300
Wayne, Pennsylvania 19087
(Address of principal executive offices)
Registrant's telephone number: (610) 975-4540
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.01 per share
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes _X_ No
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
The aggregate market value of the voting stock held by nonaffiliates of
the registrant, as of March 19, 1999, was $5,170,823.
The number of shares of the registrant's common stock, par value $.01
per share, outstanding as of March 19, 1999, was 6,169,040.
Documents Incorporated by Reference:
Document Part(s) Into Which Incorporated
(1) Proxy Statement to be used in connection Part III
with the Annual Meeting of Stockholders to
be held May 19, 1999 (the "Proxy Statement").
With the exception of the pages of the Proxy
Statement specifically incorporated by
reference herein, the Proxy Statement is not
deemed to be filed as a part of this Form 10-K.
<PAGE>
Important Factors Relating to Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements so long as those statements are
identified as forward-looking and are accompanied by meaningful cautionary
statements identifying important factors that could cause actual results to
differ materially from those projected in such statements. In connection with
certain forward-looking statements contained in this Annual Report on Form 10-K
and those that may be made in the future by or on behalf of Menley & James,
Inc., we note that there are various factors that could cause actual results to
differ materially from those set forth in any such forward-looking statements.
Among the most significant of these factors are:
o the operations and financial condition of any company that we might
acquire or with which we might merge;
o our ability to raise additional cash if it is necessary to
consummate an acquisition or infuse capital into a new business;
o our lack of experience in any new business in which we might engage;
and
o the attendant risks inherent in establishing a new line of business.
Accordingly, there can be no assurance that the forward-looking statements
contained in this Annual Report will be realized or that actual results will not
be significantly higher or lower. The inclusion of the forward-looking
statements contained in this Annual Report should not be regarded as a
representation by Menley & James, Inc. or any other person that the
forward-looking statements contained in this Annual Report will be achieved. In
light of the foregoing, readers of this Annual Report are cautioned not to place
undue reliance on the forward-looking statements contained herein.
Item 1. Business(1)
Overview
Menley & James, Inc., a Delaware corporation, was incorporated in 1990.
Until November 1998, we produced and marketed a diverse portfolio of
over-the-counter pharmaceutical and toiletry products. These brands were sold in
drug stores, supermarkets and other mass merchandisers throughout the United
States. We began our operations in 1990, with 32 brands which we acquired from
SmithKline Beecham Corporation.
Our strategy was to systematically develop and execute targeted
programs for specific brands so as to identify a product that would provide
sufficient sales response to become our lead product. Through strategic
ventures, we developed three new brands: Derifil, Humibid and Capasaicin. During
1997, we focused our development and marketing efforts on the brands Benzedrex,
Derifil and Humibid Guaifenesin Plus. In 1998, we focused on marketing the
brands Albolene, Benzedrex and Humibid. We devoted significant time and
resources to expanding the business through acquisitions. However, we concluded
that continued focus on the retail over-the-counter pharmaceutical and toiletry
marketplace would not be
- --------
(1) References to "Menley & James", "our" and "we" in this report
include Menley & James, Inc. and its wholly-owned operating subsidiary, Menley
& James Laboratories, Inc., except where the context requires otherwise.
-2-
<PAGE>
the best way to increase stockholder value and began to solicit prospective
purchasers to acquire the business.
On November 23, 1998, we sold substantially all of our assets to Numark
Laboratories, Inc. Under the terms of the sale, Numark paid us $13.43 million in
cash and assumed substantially all of our liabilities. The only assets and
liabilities which Menley & James retained were our office lease and certain
automobile and equipment leases, certain insurance policies, the corporate names
"Menley & James, Inc." and "Menley & James Laboratories, Inc." and approximately
$2.0 million in cash to pay costs and expenses associated with the sale,
including employee severance payments.
At December 31, 1998, as a result of the sale, we had the following:
o approximately $14 million in cash;
o no debt;
o an estimated $5.6 million of net operating loss carry-forwards
and an estimated $24.1 million in capital loss carry-forwards,
which may be used to offset future taxable income, if any; and
o 6,163,520 outstanding common shares.
The foregoing description of the sale is qualified in its entirety by
the full text of the Asset Purchase Agreement, dated as of August 21, 1998 (as
amended, the "Agreement") between Menley & James and Numark, which is
incorporated by reference into this Form 10-K as set forth under it in Exhibits
2.1, 2.2, and 2.3.
Strategy of Post-Sale Menley and James
Consummation of the sale terminated Menley & James' production and
marketing operations. We presently have no operating business. Since the sale,
we have been seeking to effect a business combination, outside of the
over-the-counter pharmaceutical and toiletry business, with an operating
business in an effort to maximize stockholder value.
Of the various methods and forms by which we may structure a business
combination, we are considering using a merger, an exchange of capital stock, an
acquisition of assets, a strategic investment in a minority interest or other
similar business combination. The actual form and structure of a business
combination will depend upon numerous factors pertaining to the new operating
business and its stockholders as well as potential tax and accounting treatments
afforded the business combination. Additionally, any business combination in
which we might participate will depend on the availability of attractive
candidates and our ability to finance any such business combination. We intend
to use our remaining cash, together with additional equity or debt, or a
combination of these, to achieve a business combination. The amount and nature
of any borrowings we make will depend on a number of considerations including
our capital requirements, our perceived ability to service such debt and
prevailing conditions in the financial markets and the general economy.
Lawrence D. White is Menley & James' sole employee. With the assistance
of consultants, he is administering our affairs, including financial reporting
matters, general administrative concerns and the payment of retained
liabilities. Additionally, he is implementing our strategy of pursuing a
business combination with a new operating business at the direction of the Board
of Directors and with the
-3-
<PAGE>
assistance of Warburg, Pincus Investors, L.P. Since the sale, Menley & James has
contacted approximately 35 underwriters, reviewed approximately 150 withdrawn or
postponed initial public offerings and contacted 20 of these firms, attended the
Mid-Atlantic Venture Fair, identified approximately 225 prospective venture
capital firms which may have access to potential candidates for a business
combination and contacted 18 of them, and reviewed and rejected more than 20
specific business proposals. Thus far, we have made no agreements, commitments
or understandings with any candidates for a business combination.
Executive Officer of Menley & James
Since the sale in November, 1998, Mr. White has been our sole employee
and executive officer. Mr. White, age 53, serves as our President and Chief
Executive Officer, offices he has held since Menley & James' inception in 1990.
From January 1986 to May 1990 he was Vice President of Marketing and Sales for
SmithKline Consumer Products, a division of SmithKline Beecham Corporation.
Prior to working at SmithKline Beecham Corporation, Mr. White was at Revlon's
Norcliff Thayer Division as Vice President of Marketing from 1982 to 1985, as
Director of Brand Management from 1981 to 1982, as Marketing Group Director from
1978 to 1981, and as a Brand Manager from 1977 to 1978.
Mr. White was selected by and serves at the discretion of the Board of
Directors.
Factors Which May Affect Results
Menley & James' ability to acquire and to successfully and profitably
operate a new operating business, if any, will be subject to various risk
factors including the following:
No Operating History. Risks, expenses, problems and delays, with no
assurance of profitability, are inherent in our establishment of a new line of
business in which we have no operating history.
Acquisition Risks. The success of Menley & James' acquisition strategy
is dependent on the operations, financial condition and management of the
companies with which we may merge or which we may acquire. In order to effect an
acquisition, we may incur indebtedness which we will need to repay. If we make
an investment by acquiring a minority interest in a business, then we will lack
control over the operations and strategy of the business.
Unspecified Business Risks. Until we have identified the business
opportunities in which we will attempt to obtain an interest, we cannot describe
the specific risks presented by such business. If we combine with a financially
unstable company or an entity in its early stage of development or growth, we
will be subject to the risks inherent in the business and operations of such
companies. If we combine with an entity in an industry characterized by a high
level of risk, we will be subject to the currently unascertainable risks of that
industry. Our new operating business may involve an unproven product, technology
or marketing strategy, the ultimate success of which can not be assured. Our
investment in a business opportunity may be highly illiquid and could result in
a total loss if the opportunity is unsuccessful.
-4-
<PAGE>
Need for Additional Financing. We may need to raise additional cash to
consummate a business combination or infuse capital into a new operating
business. Our limited resources and lack of operating history may make it
difficult to borrow funds on commercially acceptable terms. The incurrence of
debt would likely subject us to restrictive financial covenants as well as the
risk of interest rate fluctuations and the possible insufficiency of Menley &
James' cash flow to pay principal and interest. If we issue additional common
shares to raise additional funds, the interests of current shareholders would be
diluted and stockholders of a new operating business could possibly obtain a
controlling interest in Menley & James. Alternately, if we issue preferred
stock, the preferred stockholders may have rights or privileges senior to those
of the holders of our common shares.
Regulation. Menley & James does not intend to become an investment
company and is currently relying on the transient investment company one-year
exemption under Rule 3a-2 of the Investment Company Act of 1940. However, if we
do not acquire a new operating business within one year of the sale and continue
to invest the net proceeds of the sale in investment securities, we may be
required to register as an investment company under the 1940 Act. If we are a
registered investment company, we will be subject to a substantial increase in
the regulation of Menley & James and to the additional expenses of compliance.
Limited Management Resources and Experience. Menley & James is
currently managed solely by Mr. White, assisted by consultants on an as needed
basis. Our success will depend on our ability to attract and retain key
management and other personnel with the expertise required in connection with
the growth and development of a new operating business.
Scarcity of and Competition for Business Combinations. Many competitors
in the business of seeking mergers with and acquisitions of small private
entities have greater financial, technical, human and other resources than
Menley & James.
No Agreement for Business Combination or Other Transaction. Menley &
James may not be successful in concluding a favorable business combination and
there is no assurance that any such business combination will yield a financial
return to our stockholders.
Possible lack of Diversification. Our possible failure or inability to
diversify our business activities may subject us to the risk of economic
fluctuations within a particular business or industry.
Tax Considerations. The anticipated income tax benefit of our net
operating loss carry-forwards and capital loss carry-forwards may not be
realized or may be decreased if the time period in which they may be used
expires, or there is a change in control of Menley & James.
Limited Public Market for Common Shares. The market price of our common
shares could fluctuate significantly and there is no assurance that an active
trading market for our common shares will be developed or maintained.
-5-
<PAGE>
Certain Anti-takeover Provisions. Menley & James' charter and by-laws
include certain provisions which may have the effect of delaying, deterring or
preventing a future takeover or change in control absent approval of the Board
of Directors. Our issuance of preferred stock could also make it more difficult
for a third party to acquire a majority of the outstanding common shares and
discourage a third party from attempting to do so. Finally, anti-takeover
provisions of the Delaware General Corporation Law which restrict an "interested
stockholder" from engaging in a "business combination" could delay or prevent a
change in control of Menley & James.
Available Information
We file proxy statements, reports and other information with the
Securities and Exchange Commission ("SEC"). You may read and copy any materials
we file with the SEC at the SEC's Public Reference Room at 450 Fifth Street,
N.W. Washington, D.C. 20549. For more information on the operation of the Public
Reference Room you may call the SEC at 1-800-SEC-0330. Some of this information
may also be accessed through the SEC's Internet address at http://www.sec.gov.
Item 2. Properties.
Because of our limited need for office space after the sale, we lease
office space in Wayne, Pennsylvania for our corporate offices on a short-term
basis.
Item 3. Legal Proceedings.
There are no legal proceedings pending against Menley & James or to
which Menley & James is a party. To the knowledge of management, no such
proceedings are threatened or contemplated.
Item 4. Submission of Matters to a Vote of Security Holders.
On November 23, 1998, Menley & James stockholders held a special
meeting to consider whether to adopt and approve the agreement with Numark. Of
the 6,163,520 common shares outstanding, 4,575,146 shares were present at the
meeting. The stockholders voted to adopt and approve the Agreement as follows:
4,529,306 shares in favor; 43,415 shares against; and 2,425 shares abstaining.
-6-
<PAGE>
PART II
Item 5. Market for Registrant's Common Equity and Related Stockholder Matters.
Our common shares are traded under the symbol "MENJ." From January 21,
1992 until November 10, 1994, our common shares were traded on the Nasdaq
National Market System. As a result of our aggregate market value, trading with
respect to our common shares moved to the Nasdaq SmallCap Market on November 11,
1994. The following table shows the quarterly high and low closing bids for our
common shares on the Nasdaq SmallCap Market. Prices represent quotations between
dealers without adjustment for retail markups, markdowns and commissions and may
not necessarily represent actual transactions.
Quarter ended High Low
- ------------- ---- ---
March 31, 1997............................ $ 1 9/16 $ 1 5/32
June 30, 1997............................. 1 3/8 1 1/4
September 30, 1997........................ 1 29/32 1 5/16
December 31, 1997......................... 1 3/4 1 3/16
March 31, 1998............................ 1 7/16 1 3/16
June 30, 1998............................. 1 17/32 1 5/16
September 30, 1998........................ 2 1/4 1 1/2
December 31, 1998......................... 2 9/32 1 13/32
On March 19, 1999, the last reported closing price of our common shares
on the Nasdaq SmallCap Market was $2 5/32 per share. As of March 19, 1999, there
were approximately 69 holders of record of our common shares.
We have never paid cash dividends on our capital stock and do not
anticipate paying cash dividends in the foreseeable future. Any future
determinations to pay cash dividends will be at the discretion of the Board of
Directors and will be dependent upon our financial condition, results of any
future business combination with a new operating business, capital requirements
and such other factors as the Board of Directors deems relevant.
-7-
<PAGE>
Item 6. Selected Consolidated Financial Data.
The following table sets forth our consolidated financial data for each
of the years ended December 31, 1994 through 1998, which have been derived from
Menley & James' audited consolidated financial statements. The information set
forth below should be read in conjunction with "Management's Discussion and
Analysis of Financial Condition and Results of Operations" and the consolidated
financial statements and related notes thereto appearing elsewhere in this
report.
SELECTED FINANCIAL INFORMATION
(In thousands, except per share data)
<TABLE>
<CAPTION>
Year Ended December 31,
-----------------------------------------------------------
1994 1995 1996 1997 1998
<S> <C> <C> <C> <C> <C>
Consolidated Income Data:
Net sales.................................... $ 18,843 $14,395 $14,297 $14,446 $11,554
Cost of goods sold........................... 8,840 7,101 6,850 6,894 5,581
-------- ------- ------- ------- -------
Gross profit................................. 10,003 7,294 7,447 7,552 5,973
Selling, general and administrative
expenses.................................... 7,595 4,914 5,463 6,079 5,646
Gain on sale of brand........................ 619 -- -- -- --
Valuation adjustment......................... 12,845 -- -- -- --
Depreciation and amortization................ 1,818 1,569 1,536 1,367 1,245
-------- ------- ------- ------- -------
Income (loss) from operations................ (11,636) 811 448 106 (918)
Loss on disposal............................. -- -- -- -- 5,696
Interest (expense) income.................... (588) (237) (70) 73 197
-------- ------- ------- ------- -------
Income (loss) before income taxes ........... (12,224) 574 378 179 (6,417)
Provision for income taxes................... 657 455 416 426 698
-------- ------- ------- ------- -------
Net income (loss) applicable to common
shares...................................... $(12,881) $ 119 $ (38) $ (247) $(7,115)
======== ======= ======= ======= =======
Per share of common stock(1):
Basic income (loss) per share................ $ (2.10) $ 0.02 $ (0.01) $ (0.04) $ (1.15)
======== ======= ======= ======= =======
Weighted average common shares
outstanding................................ 6,148 6,148 6,148 6,151 6,163
======== ======= ======= ======= =======
</TABLE>
<TABLE>
<CAPTION>
At December 31,
-----------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Consolidated Balance Sheet Data:
Working capital.............................. $ 7,022 $ 6,697 $ 7,086 $ 8,372 $13,972
Total assets................................. 27,473 24,755 23,527 22,453 14,257
Long-term debt (excluding current portion) 3,100 1,005 36 -- --
Stockholders' equity......................... 21,086 21,205 21,167 20,930 13,972
</TABLE>
(1) Amounts presented assuming dilution would remain the same.
-8-
<PAGE>
Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations.
General
Menley & James commenced operations on May 29, 1990 with the
acquisition from SmithKline Beecham of the trademarks, product formulations and
production methodologies, packaging artwork and related inventories for
thirty-two over-the-counter pharmaceutical and toiletry products.
Effective November 23, 1998, we sold substantially all of our assets
and assigned substantially all of our liabilities to Numark for a purchase price
of $13,430,000. The sale resulted in a loss to us totaling approximately $6.4
million, which is comprised of pretax charges of $1.6 million for severance and
transaction-related costs, and a $4.1 million write-down to their net realizable
value of all assets sold and a provision for a valuation allowance for
previously recorded deferred tax assets totaling $0.7 million.
Results of Operations
As a result of the sale, the statements in this section may not be
meaningful in assessing the financial condition of Menley & James. Investors
should read the section entitled "Factors Which May Impact Results" for a
discussion concerning risks facing Menley & James' future business.
Year Ended December 31, 1998 Compared to Year Ended December 31, 1997
Net sales for the year ended December 31, 1998 were $11.6 million
compared to $14.4 million for the year ended December 31, 1997. The sales
decrease reflects approximately five weeks less of operations in 1998. Also, net
sales for the 1998 period reflect the continued erosion of a specific group of
our brands due to trade destocking and competitive pressure. Increased sales
from products we had marketed under agreements with three pharmaceutical firms
and sales from our other brands have largely offset the net sales decline of
this specific group of products.
Cost of goods sold for the year ended December 31, 1998 was $5.6
million, or 48% of net sales, which, as a percentage of net sales, is comparable
to the year ended December 31, 1997 cost of goods sold of 48% of net sales.
Selling, general and administrative expenses were $5.7 million for the
year ended December 31, 1998, compared to $6.1 million for the prior year. The
decrease of $433 thousand is primarily the result of the fact that we completed
the sale of our operating business effective November 23, 1998.
A pretax loss of $5.7 million on the sale of our assets has been
recorded in our financial statements for the year ended December 31, 1998, which
is comprised of pretax charges of $1.6 million for severance and
transaction-related costs, and a $4.1 million write-down to their net realizable
value of assets which were sold.
At December 31, 1998, we had a net operating loss carryforward for
federal income tax purposes of approximately $5.6 million which will expire in
the years 2005 through 2008 and a capital loss carryforward of approximately
$24.1 million. We recognized $698 thousand in tax expense, mostly noncash, for
the year ended December 31, 1998 which primarily represents a provision for a
valuation allowance against previously recorded net deferred tax assets. As of
December 31, 1998, we have
-9-
<PAGE>
recorded valuation allowances for any deferred tax assets in our consolidated
balance sheet as their realization is not assured.
Year Ended December 31, 1997 Compared to Year Ended December 31, 1996
Net sales for the year ended December 31, 1997 were $14.4 million
compared to $14.3 million for the comparable period of 1996. Sales for 1997
benefitted from our sales and marketing agreements entered into during 1996.
These agreements include Humibid Guaifenesin Plus, a nonprescription formulation
of the Rx drug, Humibid; Derifil, an internal deodorant; and Capsaicin, a
generic version of Zostrix(R) cream. Net sales for these brands totaled $1.7
million, an increase of $762 thousand over the year ended December 31, 1996. Net
sales of our remaining brands decreased $612 thousand compared to 1996. The
decline in sales is due to continued competition and trade destocking pressures.
Cost of goods sold for the year 1997 was $6.9 million, or 48% of net
sales, which is comparable to the 1996 cost of goods sold of $6.9 million, or
48% of net sales in 1996.
Selling, general and administrative expenses were $6.1 million, or 42%
of net sales for the year ended December 31, 1997, as compared to $5.5 million
or 38% for the prior year. The $616 thousand increase in expense is primarily a
result of an increase in Benzedrex advertising costs along with marketing costs
associated with the products under the our sales and marketing agreements. Our
sales force, and our network of independent brokers, work directly with the
major retail customers to focus marketing support behind individual Menley &
James products at the retail store level.
At December 31, 1997, we had a net operating loss carryforward for
federal income tax purposes of approximately $5.7 million which may be used to
offset future taxable income. These net operating loss carryforwards will expire
during the years 2005 through 2008. We recognized $426 thousand in tax expense,
mostly noncash, for the year ended December 31, 1997. The effective tax rate
exceeded the statutory federal tax rate primarily as a result of the
amortization of product lines and trade names, which is not deductible for tax
purposes. We had net deferred tax assets of $692 thousand in our consolidated
balance sheet as of December 31, 1997, which is primarily made up of two items,
net operating loss carryforwards and future deductible expenses.
Impact of Inflation
We believe that, to date, inflation has not had a significant impact on
our operations.
Liquidity and Capital Resources
At December 31, 1998, we had working capital of $14 million. Working
capital was primarily provided by the net proceeds from the sale of assets to
Numark. We have no bank debt outstanding at December 31, 1998.
At the present time, we have minimal cash requirements and operating
activities. Our strategic focus in the year ahead is to effect a business
combination with a new operating business which Menley & James believes has
potential to increase stockholder value. It is anticipated that Menley & James
would use cash, equity, debt or a combination of these to achieve a business
combination. We may borrow funds
-10-
<PAGE>
to increase the amount of capital available for a business combination or
otherwise finance the operation of the new operating business. Cash of $13.4
million is invested in short-term highly liquid funds.
Impact of Year 2000
We are currently not engaged in any substantial business operations,
and management, therefore, does not believe that computer problems associated
with the change of year to the year 2000 will have any material effect on our
operations. However, the possibility exists that we may merge with or acquire a
business that will be negatively affected by the "Year 2000" problem. The effect
of such issues on us in the future can not be predicted with any accuracy until
such time as we identify a merger or acquisition target.
Item 7A. Quantitative and Qualitative Disclosure About Market Risk.
Not applicable.
-11-
<PAGE>
Item 8. Financial Statements and Supplementary Data.
REPORT OF INDEPENDENT AUDITORS
Board of Directors
Menley & James, Inc.
We have audited the accompanying consolidated balance sheets of Menley
& James, Inc. as of December 31, 1998 and 1997, and the related consolidated
statements of operations, stockholders' equity, and cash flows for each of the
three years in the period ended December 31, 1998. Our audits also included the
financial statement schedule listed in the Index at Item 14(a). These financial
statements and schedule are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements and
schedule based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the consolidated financial position of
Menley & James, Inc. at December 31, 1998 and 1997, and the consolidated results
of its operations and its cash flows for each of the three years in the period
ended December 31, 1998, in conformity with generally accepted accounting
principles. Also, in our opinion, the related financial statement schedule, when
considered in relation to the basic financial statements taken as a whole,
presents fairly in all material respects the information set forth therein.
/s/ Ernst & Young LLP
-------------------------
ERNST & YOUNG LLP
Philadelphia, Pennsylvania
March 11, 1999
-12-
<PAGE>
MENLEY & JAMES, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands)
<TABLE>
<CAPTION>
December 31,
----------------------
1997 1998
---- ----
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents ............................................ $ 2,879 $ 14,062
Accounts receivable, net of allowances of $464 in 1997 ............... 2,474 --
Inventory ............................................................ 2,844 --
Prepaid expenses ..................................................... 1,006 195
Deferred tax asset ................................................... 692 --
-------- --------
Total current assets ................................................. 9,895 14,257
Property and equipment, net .............................................. 1,435 --
Product lines, trade names and packaging designs, net .................... 11,123 --
-------- --------
Total assets ......................................................... $ 22,453 $ 14,257
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ..................................................... $ 840 $ 16
Accrued expenses ..................................................... 647 269
Current maturities of long-term debt ................................. 36 --
-------- --------
Total current liabilities ............................................ 1,523 285
Preferred stock, $1 par value, authorized 5,000,000 shares,
none issued and outstanding .......................................... -- --
Stockholders' equity:
Common stock, $.01 par value, authorized 15,000,000 shares, issued and
outstanding was 6,163,520 shares in 1997 and 1998 ................. 62 62
Additional paid-in capital ........................................... 45,463 45,620
Accumulated deficit .................................................. (24,595) (31,710)
-------- --------
Total stockholders' equity ............................................... 20,930 13,972
-------- --------
Total liabilities and stockholders' equity ........................... $ 22,453 $ 14,257
======== ========
</TABLE>
See accompanying notes.
-13-
<PAGE>
MENLEY & JAMES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
<TABLE>
<CAPTION>
Year Ended December 31,
---------------------------------------
1996 1997 1998
---- ---- ----
<S> <C> <C> <C>
Net sales .................................. $ 14,297 $ 14,446 $ 11,554
Cost of goods sold ......................... 6,850 6,894 5,581
-------- -------- --------
Gross profit ............................... 7,447 7,552 5,973
Selling, general and administrative expenses 5,463 6,079 5,646
Depreciation and amortization .............. 1,536 1,367 1,245
-------- -------- --------
Income (loss) from operations .............. 448 106 (918)
Loss on disposal ........................... -- -- 5,696
Interest (expense) income .................. (70) 73 197
-------- -------- --------
Income (loss) before income taxes .......... 378 179 (6,417)
Provision for income taxes ................. 416 426 698
-------- -------- --------
Net loss ................................... $ (38) $ (247) $ (7,115)
======== ======== ========
Basic loss per share ....................... $ ( 0.01) $ (0.04) $ (1.15)
======== ======== ========
Diluted loss per share ..................... $ (0.01) $ (0.04) $ (1.15)
======== ======== ========
Weighted average number of common shares
outstanding - basic ...................... 6,148 6,151 6,163
======== ======== ========
Weighted average number of common shares
outstanding - diluted .................... 6,148 6,151 6,163
======== ======== ========
</TABLE>
See accompanying notes.
-14-
<PAGE>
MENLEY & JAMES, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(In thousands)
<TABLE>
<CAPTION>
Additional Total
Common Paid-in Accumulated Stockholders'
Stock Capital Deficit Equity
--------- ---------- ---------- ---------
<S> <C> <C> <C> <C>
Balance, December 31, 1995 $ 61 $ 45,454 $ (24,310) $ 21,205
Net loss.............................. (38) (38)
--------- ---------- ---------- ---------
Balance, December 31, 1996 61 45,454 (24,348) 21,167
Net loss.............................. (247) (247)
Exercise of stock options ............ 1 9 10
--------- ---------- ---------- ---------
Balance, December 31, 1997 62 45,463 (24,595) 20,930
Net loss.............................. (7,115) (7,115)
Employee stock options ............... 157 157
--------- ---------- ---------- ---------
Balance, December 31, 1998 ............... $ 62 $ 45,620 $ (31,710) $ 13,972
========= ========== ========== =========
</TABLE>
See accompanying notes.
-15-
<PAGE>
MENLEY & JAMES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
<TABLE>
<CAPTION>
Year Ended December 31,
---------------------------------------------
1996 1997 1998
---- ---- ----
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss ............................................... $ (38) $ (247) $ (7,115)
Adjustments to reconcile net loss to net
cash provided by (used in) operating activities:
Loss on disposal .................................. -- -- 5,696
Depreciation and amortization ..................... 1,536 1,367 1,245
Compensation expense .............................. -- -- 157
Amortization of deferred financing costs .......... 38 28 --
Deferred income taxes ............................. 427 373 692
Changes in operating assets and liabilities:
Accounts receivable ............................. 412 247 300
Inventory ....................................... 423 558 (775)
Prepaid expenses ................................ (77) (428) 657
Accounts payable ................................ 294 (269) (565)
Accrued expenses ................................ (32) 106 (1,236)
-------- -------- --------
Net cash provided by (used in) operating activities .. 2,983 1,735 (944)
Cash flows provided by (used in) investing activities:
Proceeds from Sale, net of cash sold .............. -- -- 12,344
Property purchases, net of capital lease obligation (314) (397) (181)
-------- -------- --------
Net cash provided by (used in) investing activities (314) 12,163
Cash flows provided by (used in) financing activities:
Proceeds from issuance of common stock, net ....... -- 10 --
Repayment of borrowings ........................... (1,452) (674) (36)
-------- -------- --------
Net cash provided by (used in) financing activities (1,452) (664) (36)
Net increase in cash ...................................... 1,217 674 11,183
Cash and cash equivalents, beginning of year .............. 988 2,205 2,879
-------- -------- --------
Cash and cash equivalents, end of year .................... $ 2,205 $ 2,879 $ 14,062
======== ======== ========
</TABLE>
See accompanying notes.
-16-
<PAGE>
MENLEY & JAMES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1 - Organization and Basis of Presentation
Menley & James, Inc. ("the Company") and its wholly owned subsidiary,
Menley & James Laboratories, Inc. were incorporated in Delaware in 1990. Prior
to November 23, 1998, the Company, through Menley & James Laboratories, Inc.,
marketed and distributed a portfolio of over-the-counter pharmaceutical and
toiletries products to drugstores, supermarkets, and other mass merchandisers
throughout the United States. Effective November 23, 1998, the Company sold
substantially all of its assets and assigned substantially all of its
liabilities to Numark Laboratories, Inc. for a purchase price of $13,430,000
(the "Sale").
The Sale resulted in a loss to the Company totaling approximately $6.4
million, which is comprised of pretax charges of $1.6 million for severance and
transaction-related costs and a $4.1 million write-down to their net realizable
value of all assets sold and a provision for a valuation allowance for
previously recorded deferred tax assets totaling $0.7 million.
At December 31, 1998, the Company had no operating business.
Note 2 - Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of the
Company and its wholly owned subsidiary, Menley & James Laboratories, Inc. All
material intercompany transactions and accounts have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the amounts reported in the financial statements and
accompanying notes. Actual results could differ from those estimates.
Revenue Recognition
Revenue is recognized when products are shipped. Provisions for
estimated returns and cash discounts are made when revenues are recognized.
Cash Equivalents
Cash equivalents consist of highly liquid temporary cash investments
with original maturities of less than three months when purchased which are
valued at cost plus accrued interest, which approximate market value.
Inventories
Inventories at December 31, 1997 are stated at the lower of cost or
market by the first-in, first-out method.
Product Lines, Trade Names and Packaging Designs
Substantially all of the product lines and trade names were recorded at
the time of the acquisition in 1990 and allocated among the brands based on
valuations performed at that time.
Packaging designs were being amortized over five years. Product lines
and trade names were being amortized over fourteen years. Accumulated
amortization at December 31, 1997 was $9.8 million. Amortization expense
relating to product lines, trade names and packaging designs was $1.2 million,
$1.1 million and $965 thousand for the years 1996, 1997 and 1998, respectively.
-17-
<PAGE>
MENLEY & JAMES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 2 - Summary of Significant Accounting Policies (Continued)
Property and Equipment
Property and equipment as of December 31, 1997 was carried at cost less
accumulated depreciation. Depreciation was computed using the straight-line
method over the estimated useful lives of the assets. Accumulated depreciation
at December 31, 1997 was $1.9 million. Depreciation expense was $380,000,
$280,000 and $275,000 for years 1996, 1997 and 1998, respectively.
Consumer Promotions
The estimated redemption value of coupons was charged to marketing and
promotion expense when the coupons were distributed to the consumer. The
incremental product cost of "two-for-one" or "bonus pack" offers was charged to
advertising and promotion expense as sales of the related product occurred.
Income Taxes
The liability method is used in accounting for income taxes. Under this
method, deferred tax assets and liabilities are determined based on differences
between financial reporting and tax bases of assets and liabilities and are
measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse.
Stock-Based Compensation.
The Company has elected to follow Accounting Principles Board Opinion
No. 25, "Accounting for Stock Issued to Employees" (APB 25) and related
interpretations in accounting for our employee stock options because the
alternative fair value accounting provided for under FASB Statement No. 123,
"Accounting for Stock-Based Compensation," requires use of option valuation
models that were not developed for use in valuing employee stock options. The
effect of applying Statement No. 123's fair value method to the Company's
stock-based awards results in pro forma net loss and loss per share that are not
materially different from amounts reported.
Note 3 - Inventories
Inventories at December 31, 1997 consist of the following (in thousands):
Raw materials............................. $ 1,095
Work in process........................... 280
Finished goods............................ 1,469
------
$ 2,844
======
Note 4 - Long-Term Debt
The Company leased computer equipment under a capital lease which was
recorded at its fair market value. As of December 31, 1997, the Company had
current obligations under a capital lease which totaled $36 thousand.
This lease was canceled by the Company during 1998.
The Company had no long-term debt at December 31, 1997 or 1998.
At December 31, 1997, there was no amount outstanding under the
Company's revolving credit facility which was terminated on November 23, 1998,
the date of the Sale.
Interest payments for the years 1996, 1997 and 1998 were approximately
$103,000, $5,000 and $0, respectively.
-18-
<PAGE>
MENLEY & JAMES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 5 - Income Taxes
Significant components of the Company's deferred tax assets and
liabilities at December 31, were as follows (in thousands):
<TABLE>
<CAPTION>
1996 1997 1998
---- ---- ----
<S> <C> <C> <C>
Deferred tax liabilities:
Prepaid expenses and other ..................................... $ 155 $ 282 $ --
Amortization of organizational costs and
packaging designs ............................................ 348 255 --
Depreciation ................................................... 309 231 --
-------- -------- --------
Total deferred tax liabilities ................................... 812 768 --
-------- -------- --------
Deferred tax assets:
Net operating loss carryforwards ............................... 2,768 2,317 1,993
Capital loss carryforwards ..................................... -- -- 9,162
Promotional expenses ........................................... 174 157 --
Nondeductible allowances and reserves .......................... 245 220 --
Other .......................................................... 80 75 71
-------- -------- --------
Total deferred tax assets ........................................ 3,267 2,769 11,226
Valuation allowance for deferred tax assets ...................... (1,390) (1,309) (11,226)
-------- -------- --------
Deferred tax assets, net of valuation allowance .................. 1,877 1,460 --
-------- -------- --------
Net deferred tax assets .......................................... $ 1,065 $ 692 $ --
======== ======== ========
</TABLE>
Significant components of the provision for income taxes are as
follows (in thousands):
<TABLE>
<CAPTION>
1996 1997 1998
---- ---- ----
<S> <C> <C> <C>
Current:
Federal ...................................................... $ 9 $ 25 $ --
State ........................................................ (20) 28 6
-------- -------- --------
Total current .................................................... (11) 53 6
Deferred ......................................................... 427 373 692
-------- -------- --------
Provision for income taxes ..................................... $ 416 $ 426 $ 698
======== ======== ========
</TABLE>
The reconciliation between the Company's provision for income taxes and
the U.S. federal statutory tax rates is (in thousands):
<TABLE>
<CAPTION>
1996 1997 1998
---- ---- ----
<S> <C> <C> <C>
Tax at U.S. statutory rates .................................... $ 129 $ 61 $ (2,182)
State taxes, net of federal tax benefit ........................ 19 94 (1)
Product lines and other amortization
not deductible for tax ....................................... 375 339 292
Tax loss in excess of book loss on sale of business ............ -- -- (6,819)
Change in federal valuation allowance .......................... -- (81) 9,311
Other .......................................................... (107) 13 97
-------- -------- --------
Provision for income taxes ..................................... $ 416 $ 426 $ 698
======== ======== ========
</TABLE>
The Company has approximately $5.6 million of tax return net operating
loss carryforwards currently available on an unlimited basis to offset federal
net taxable income and a $24.1 million capital loss carryforward.
These loss carryforwards expire in the years 2005 through 2008.
-19-
<PAGE>
MENLEY & JAMES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 6 - Leases
Rental expense for operating leases for the years 1996, 1997 and 1998
was $150,000, $158,000 and $151,000 respectively.
Note 7 - Common Stock and Stock Options
In 1991, the Board of Directors adopted, and the stockholders approved,
a stock option plan which authorized the grant of stock options with respect to
380,000 shares of the Company's common stock and granted options to purchase
289,180 shares of common stock at an exercise price of $7.89 per share. On
February 1, 1996, 224,960 options were revalued reducing the exercise price from
$7.89 per share to $1.25 per share, which reflected the share price at the close
of business February 1, 1996. During 1996, options were granted to purchase
15,000 and 30,000 shares of common stock at exercise prices of $1.19 and $1.56,
respectively. During 1997, options were granted to purchase 30,000 shares of
common stock at an exercise price of $1.38 per share. Additionally, during 1997,
options to purchase 15,000 shares of common stock were exercised at an exercise
price of $0.69 per share and options to purchase 30,000 shares of common stock
expired. During 1998, options were granted to purchase 30,000 shares of common
stock at an exercise price of $1.50 per share and options to purchase 7,600
shares at $1.25 per share were forfeited. Additionally, pursuant to the Sale,
the life of options to purchase 179,360 shares of common stock held by employees
was extended such that they will remain exercisable for a period of one year
after the termination of the employees. This change resulted in $156,940 of
compensation expense which was recorded in the loss on the Sale. At December 31,
1998, 307,360 options are outstanding, vested and exercisable at prices ranging
from $1.25 to $1.56 per share.
Note 8 - Commitments
The Company had license and sales and marketing agreements to
manufacture and/or market certain products. Under these agreements, the Company
was required to pay royalties based upon various percentages of net sales and/or
net profits. Additionally, pursuant to the above agreements, the Company was
entitled to receive monies based on losses, if any, incurred during the year on
certain of the products. Net sales of all products under agreements, for the
years ended 1996, 1997 and 1998 were equal to 9.3%, 12.5% and 11.7%,
respectively, of total net sales. Royalty expense, net, for the years 1996, 1997
and 1998 was $23,000, $578,000 and $615,000, respectively.
Note 9 - Supplemental Information
Advertising expense for the years 1996, 1997 and 1998 was $613,000,
$1.0 million and $713,000, respectively.
-20-
<PAGE>
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.
None.
PART III
Item 10. Directors and Executive Officers of the Registrant.
Information concerning directors, appearing under the caption "Item 1.
Election of Directors" in Menley & James' Proxy Statement (the "Proxy
Statement") to be filed with the SEC in connection with the Annual Meeting of
Stockholders scheduled to be held on May 19, 1999, and information concerning
executive officers, appearing under the caption "Item 1. Business - Executive
Officer of Menley & James" in Part I of this Form 10-K, are incorporated herein
by reference in response to this Item 10.
Item 11. Executive Compensation.
The information concerning executive compensation contained in the
section titled "Executive Compensation and Related Information" in the Proxy
Statement is incorporated herein by reference in response to this Item 11.
Item 12. Security Ownership of Certain Beneficial Owners and Management.
The information concerning security ownership of certain beneficial
owners and management contained in the section titled "Security Ownership of
Certain Beneficial Owners and Management" in the Proxy Statement is incorporated
herein by reference in response to this Item 12.
Item 13. Certain Relationships and Related Transactions.
The information concerning certain relationships and related
transactions contained under the caption "Certain Relationships and Related
Transactions" in the Proxy Statement is incorporated herein by reference in
response to this Item 13.
-21-
<PAGE>
PART IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K.
(a) Exhibits
(1) The following Consolidated Financial Statements of Menley &
James, Inc. are included in Item 8 of this report:
Consolidated Balance Sheets as of December 31, 1997 and 1998.
Consolidated Statements of Operations for the years ended
December 31, 1996, 1997 and 1998.
Consolidated Statements of Stockholders' Equity for the years
ended December 31, 1996, 1997 and 1998.
Consolidated Statements of Cash Flows for the years ended
December 31, 1996, 1997 and 1998.
Notes to Consolidated Financial Statements.
(2) The following Consolidated Financial Statement Schedule of Menley
& James, Inc. as required by Item 8 of Form 10-K and Item 14(d)
of Form 10-K for the years ended December 31, 1996, 1997 and 1998
is filed as part of this report:
Page Schedule
---- --------
25 Schedule II -- Valuation and Qualifying Accounts and
Reserves.
All schedules other than the above have been omitted, because they are
not required or the information to be set forth therein is included in
the financial statements or in the notes thereto.
(3) Listing of Exhibits (An exhibit index immediately preceding the
exhibits indicates the page number where each exhibit can be
found; Menley & James will furnish, upon request, any exhibit
listed herein upon the payment of a fee not to exceed reasonable
expenses incurred by Menley & James in furnishing such exhibit):
2.1 Asset Purchase Agreement dated as of August 21, 1998 by and
among Menley & James, Inc., Menley & James Laboratories,
Inc. and Numark Laboratories, Inc. ( Incorporated by
reference to the Company's Quarterly Report on Form 10-Q
filed November 16, 1998. Commission File No. 000-19788).
2.2 Amendment No. 1 to Asset Purchase Agreement dated as of
October 13, 1998 by and among Menley & James, Inc., Menley &
James Laboratories, Inc. and Numark Laboratories, Inc.
(Incorporated by reference to the Company's Quarterly Report
on Form 10-Q filed November 16, 1998. Commission File No.
000-19788).
2.3 Amendment No. 2 to Asset Purchase Agreement dated as of
November 11, 1998 by and among Menley & James, Inc., Menley
& James Laboratories, Inc. and Numark Laboratories, Inc.
(Incorporated by reference to the Quarterly Report of Menley
& James, Inc. on Form 10-Q filed November 16, 1998.
Commission File No. 000-19788).
*3.1 Restated Certificate of Incorporation of Menley & James,
Inc., as amended on March 19, 1991.
*3.2 By-Laws of Menley & James, Inc., amended as of November 26,
1991.
*4.1 Specimen Stock Certificate for Common Stock $.01 par value.
-22-
<PAGE>
*10.2 1991 Stock Option Plan of Menley & James, Inc., as amended
and restated by Amendment 1998-1 on September 9, 1998
(Incorporated by reference to the Quarterly Report of Menley
& James, Inc. on Form 10-Q filed November 16, 1998.
Commission File No. 000-19788).**
*10.9 Form of Agreement, dated as of November 20, 1991, by and
between Menley & James, Inc. and Warburg, Pincus Investors,
L.P.
10.22 Severance Agreement, dated as of September 24, 1998 between
Menley & James, Inc. and Greg L. Kearl (Incorporated by
reference to the Quarterly Report of Menley & James, Inc. on
Form 10-Q filed November 16, 1998. Commission File No. 000-
19788).**
10.23 Severance Agreement, dated as of October 15, 1995, between
Menley & James, Inc. and Lawrence D. White. (Incorporated by
reference to the Annual Report of Menley & James, Inc. on
Form 10-K filed March 27, 1996. Commission File No.
000-19788).**
10.26 Letter, dated as of February 13, 1996, repricing outstanding
stock options under the Company's 1991 Stock Option Plan.
(Incorporated by reference to the Annual Report of Menley &
James, Inc. on Form 10-K filed March 27, 1996. Commission
File No. 000- 19788).**
10.27 Form of Director Stock Option Agreement. (Incorporated by
reference to the Annual Report of Menley & James, Inc. on
Form 10-K filed March 28, 1997. Commission File No.
000-19788).**
10.29 Stockholders' Agreement dated as of August 21, 1998 by an
among Warburg, Pincus Investors, L.P., Lawrence D. White and
Numark Laboratories, Inc. (Incorporated by reference to the
Quarterly Report of Menley & James, Inc. on Form 10-Q filed
November 16, 1998. Commission No. 000-19788).
*22.1 List of Subsidiaries.
27.1 Financial Data Schedule for the year ended December 31,
1998, submitted electronically to the Securities and
Exchange Commission.
* Filed as an exhibit to the Registration Statement on Form S-1,
Registration No. 33-44260, declared effective by the Securities and
Exchange Commission on January 17, 1992, which is incorporated by
reference herein.
**Management contract or compensatory benefit plan or arrangement.
(b) Report filed on Form 8-K during the last quarter of 1998:
On December 3, 1998, Menley & James, Inc. filed a Current Report on
Form 8-K regarding the consummation of the sale and assignment of
substantially all of the assets of Menley and James on November 23,
1998, pursuant to the Asset Purchase Agreement dated August 21, 1998,
and related amendments by and among Menley & James, Inc., Menley &
James Laboratories, Inc. and Numark Laboratories, Inc.
(c) Exhibits -- The response to this portion of Item 14 is submitted as a
separate section of this report.
(d) Financial Statement Schedules -- The response to this portion of Item
14 is submitted as a separate section of this report.
-23-
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
MENLEY & JAMES, INC.
/s/ Lawrence D. White
-------------------------------------
Lawrence D. White
President and Chief Executive Officer
Date: March 23, 1999
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
Signature Title Date
--------- ----- ----
<S> <C> <C>
/s/ Lawrence D. White Director, Chairman of the Board, March 23, 1999
- --------------------------- President and Chief Executive Officer
(Lawrence D. White) (Principal Executive Officer)
/s/ Greg L. Kearl Director, Secretary and Treasurer March 23, 1999
- ---------------------------
(Greg L. Kearl)
/s/ Peter J. Carr Director March 23, 1999
- ---------------------------
(Peter J. Carr)
/s/ James T. McMillan, II Director March 23, 1999
- ---------------------------
(James T. McMillan, II)
/s/ Bruce W. Simpson Director March 23, 1999
- ---------------------------
(Bruce W. Simpson)
/s/ James E. Thomas Director March 23, 1999
- ---------------------------
(James E. Thomas)
</TABLE>
-24-
<PAGE>
SCHEDULE II
MENLEY & JAMES, INC.
VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
(In thousands)
The Company's valuation accounts were as follows:
<TABLE>
<CAPTION>
Balance at Charged to Balance at
Beginning Costs and End of
of Period Expenses Deductions Period
---------- ---------- ---------- ----------
<S> <C> <C> <C> <C>
For the year ended December 31, 1996
Deducted from asset accounts:
Allowance for doubtful accounts.................... $ 170 $ 50 $ 208 $ 12
Reserve for cash discounts......................... 48 328 330 46
Reserve for returns and allowances ................ 435 1,938 1,907 466
Reserve for inventory obsolescence ................ 5 112 112 5
Valuation allowance for deferred tax assets ....... 1,390 -- -- 1,390
------ ------ ------ ------
Totals........................................... $2,048 $2,428 $2,557 $1,919
====== ====== ====== ======
For the year ended December 31, 1997
Deducted from asset accounts:
Allowance for doubtful accounts.................... $ 12 $ 38 $ 24 $ 26
Reserve for cash discounts......................... 46 331 329 48
Reserve for returns and allowances ................ 466 1,558 1,634 390
Reserve for inventory obsolescence ................ 5 257 201 61
Valuation allowance for deferred tax assets ....... 1,390 -- 81 1,309
------ ------ ------ ------
Totals........................................... $1,919 $2,184 $2,269 $1,834
====== ====== ====== ======
For the year ended December 31, 1998
Deducted from asset accounts:
Allowance for doubtful accounts.................... $ 26 $ -- $ 26 $ --
Reserve for cash discounts......................... 48 261 309 --
Reserve for returns and allowances ................ 390 1,168 1,558 --
Reserve for inventory obsolescence ................ 61 74 135 --
Valuation allowance for deferred tax assets ....... 1,309 9,917 -- 11,226
------ ------- ------ -------
Totals............................................ $1,834 $11,420 $2,028 $11,226
====== ======= ====== =======
</TABLE>
In 1996 and 1997, deductions from the allowance for doubtful accounts
represent uncollectible accounts written off, net of recoveries. Deductions from
the reserve for cash discounts represent discounts taken by customers during the
periods. Deductions from the reserve for returns and allowances represent claims
authorized during the periods. Deductions from the reserve for inventory
obsolescence represent inventories written off. In 1998, deductions also include
the write off of valuation allowances related to assets sold.
-25-
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains financial information extracted from the Consolidated
Balance Sheet at December 31, 1998 and the Consolidated Statement of Operations
for the Year Ended December 31, 1998.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> DEC-31-1998
<CASH> 14,062
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 14,257
<PP&E> 0
<DEPRECIATION> 0
<TOTAL-ASSETS> 14,257
<CURRENT-LIABILITIES> 285
<BONDS> 0
0
0
<COMMON> 62
<OTHER-SE> 13,910
<TOTAL-LIABILITY-AND-EQUITY> 14,257
<SALES> 11,554
<TOTAL-REVENUES> 11,554
<CGS> 5,581
<TOTAL-COSTS> 5,581
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (197)
<INCOME-PRETAX> (6,417)
<INCOME-TAX> 698
<INCOME-CONTINUING> (7,115)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (7,115)
<EPS-PRIMARY> (1.15)
<EPS-DILUTED> (1.15)
</TABLE>
